Gainor et al. discovered that low response rates to PD-1/PD-L1 inhibitor therapy in patients with NSCLC were associated with epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase rearrangements (ALK) [27]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.